Emily Bevan
Impact in
- Infectious Diseases top 0.5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Neurology top 2%
- Long-Term Effects of COVID-19
Papers in
-
- COVID-19 Clinical Research Studies 19
- SARS-CoV-2 and COVID-19 Research 4
-
- Long-Term Effects of COVID-19 9
- Journals
- The Lancet (6 papers)JAMA (6 papers)Nature (4 papers)The Lancet Respiratory Medicine (4 papers)EClinicalMedicine (2 papers)
- Partner nations
- United KingdomVietnamAustralia
In The Last Decade
Emily Bevan
34 papers receiving 3.8k citations
Emily Bevan's Hit Papers
Peers
Comparison fields: 5 of 113
- Infectious Diseases 2.3k
- Neurology 522
- Genetics 533
- Applied Microbiology and Biotechnology 43
- Internal Medicine 45
Countries citing papers authored by Emily Bevan
This map shows the geographic impact of Emily Bevan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Bevan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Bevan more than expected).
Fields of papers citing papers by Emily Bevan
This network shows the impact of papers produced by Emily Bevan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Bevan. The network helps show where Emily Bevan may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Hit paper breakdown → | 2022 | 310 |
| 5 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 6 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 7 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 8 | 2021 | 213 | |
| 9 | 2021 | 166 | |
| 10 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 11 | 2022 | 105 | |
| 12 | 2022 | 100 | |
| 13 | Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis Hit paper breakdown → | 2024 | 94 |
| 14 | 2022 | 87 | |
| 15 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 16 | 2021 | 72 | |
| 17 | Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease Hit paper breakdown → | 2024 | 65 |
| 18 | 2023 | 60 | |
| 19 | 2023 | 46 | |
| 20 | 2023 | 35 |
About Emily Bevan
Emily Bevan is a scholar working on Infectious Diseases, Neurology, Genetics, Geriatrics and Gerontology and Nutrition and Dietetics, having authored 35 papers that have together received 4k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (19 papers), Long-Term Effects of COVID-19 (9 papers), Genetic Associations and Epidemiology (7 papers), SARS-CoV-2 and COVID-19 Research (4 papers), Sleep and related disorders (1 paper), Antibiotics Pharmacokinetics and Efficacy (1 paper), Kawasaki Disease and Coronary Complications (1 paper) and Vitamin C and Antioxidants Research (1 paper). The work is most often cited by research in Infectious Diseases (2.3k citations), Neurology (522 citations), Genetics (533 citations), Applied Microbiology and Biotechnology (43 citations) and Internal Medicine (45 citations). Emily Bevan has collaborated with scholars based in United Kingdom, Vietnam and Australia. Their work appears in journals such as The Lancet, JAMA, Nature, The Lancet Respiratory Medicine and EClinicalMedicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.